Lyell Immunopharma (LYEL) Equity Ratio: 2020-2025
Historic Equity Ratio for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to 0.81.
- Lyell Immunopharma's Equity Ratio fell 5.87% to 0.81 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.81, marking a year-over-year decrease of 5.87%. This contributed to the annual value of 0.78 for FY2024, which is 10.69% down from last year.
- According to the latest figures from Q3 2025, Lyell Immunopharma's Equity Ratio is 0.81, which was up 4.03% from 0.78 recorded in Q2 2025.
- In the past 5 years, Lyell Immunopharma's Equity Ratio ranged from a high of 0.89 in Q1 2023 and a low of 0.78 during Q2 2025.
- Its 3-year average for Equity Ratio is 0.84, with a median of 0.87 in 2024.
- As far as peak fluctuations go, Lyell Immunopharma's Equity Ratio skyrocketed by 356.07% in 2021, and later declined by 10.69% in 2024.
- Quarterly analysis of 5 years shows Lyell Immunopharma's Equity Ratio stood at 0.82 in 2021, then climbed by 7.76% to 0.89 in 2022, then dropped by 1.75% to 0.87 in 2023, then decreased by 10.69% to 0.78 in 2024, then dropped by 5.87% to 0.81 in 2025.
- Its Equity Ratio was 0.81 in Q3 2025, compared to 0.78 in Q2 2025 and 0.78 in Q1 2025.